Stockholm - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company's Full Year Report for the period January December 2019 on Thursday, February 6, 2020, at 08:00 a.m. CET.

BioArctic invites to an audiocast with teleconference (in English) for investors, analysts and media on February 6, at 09:30 - 10:30 a.m. CET.

Gunilla Osswald, CEO, and Jan Mattsson, CFO, to present BioArctic and comment on the Full Year Report for the period January - December 2019 followed by a Q&A-session.

To attend, please dial-in at one of the numbers below, from

Sweden: + 46 8 505 583 55

Denmark: + 45 354 455 77

Germany: + 49 691 380 3452

The Netherlands: + 31 207 095 189

Norway: + 47 235 002 43

Switzerland: + 41 225 805 976

UK: + 44 333 300 9265

US: + 1 833 823 0589

Webcast: https://tv.streamfabriken.com/bioarctic-q4-2019

The webcast will afterwards also be available on demand at BioArctic's corporate website www.bioarctic.com, Investors, Financial presentations.

Contact:

Jan Mattsson

Tel: + 46 70 352 27 72

Email: jan.mattsson@bioarctic.se

About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with its strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic's B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B).

(C) 2020 Electronic News Publishing, source ENP Newswire